Oncology research focuses on the treatment and prevention of cancer in the body and blood. These clinical trials may evaluate new medications, treatments or interventions for cancer, cancer prevention and methods to reduce side effects from treatment.

Common Types of Cancer:

•    Lung cancer
•    Breast cancer
•    Prostate cancer
•    Colorectal cancer
•    Pancreatic cancer
•    Hematologic (blood) cancers such as lymphoma and leukemia

To learn more about participating in a clinical trial, please contact us at 

1-800-836-0388 or clinical.research@guthrie.org

 

 

Title: A Phase 3 Randomized, Double-Blind, Active-Controlled
Study of Palazestrant with Ribociclib Versus Letrozole with
Ribociclib for the First-Line Treatment of ER+, HER2
Advanced Breast Cancer (OPERA-02)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT07085767
Title: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT06016738
Title: ASCENT A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Gilead Sciences
Details (Identifier #): NCT05633654
Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT04964934
Title: NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: NRG Oncology
Details (Identifier #): NCT04852887
Title: NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant
Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy
in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ? 25 (OFSET)
Department: Oncology
Diagnosis: Cancer - Breast
Sponsors: National Cancer Institute
Details (Identifier #): NCT05879926
Title: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: ALLIANCE
Details (Identifier #): NCT05812807
Title: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Basnet, Alina

Sponsors: ALLIANCE
Details (Identifier #): NCT05812807
Title: S1501, Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: SWOG Cancer Research Network
Details (Identifier #): NCT03418961
Title: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III
Study
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: SWOG Cancer Research Network
Details (Identifier #): NCT05929768
Showing 1-10 of 10 Results